H.C. Wainwright analyst Douglas Tsao downgraded Amryt Pharma to Neutral from Buy with a price target of $14.50, down from $18, after the company announced last week that it has agreed to be acquired by Chiesi. His new price target of $14.50 is based on the acquisition price agreed with Chiesi Farmaceutici.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMYT: